Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead

Lilly is a good pick...but this one is better. Not exactly David vs. Goliath Sure, Vertex is much smaller than Lilly, with the latter's massive market cap at over $840 billion. But it's by no means small: Vertex's market cap tops $120 billion, making it one of the world's largest drugmakers. One nice plus for Vertex is that it enjoys a monopoly in treating the underlying cause of the rare genetic disease cystic fibrosis (CF). All four approved therapies that fit the bill are marketed by Vertex, including it ...